Vanflyta (Quizartinib Dihydrochloride) Patent Expiration, LOE Window & CMS Spending

Vanflyta (Quizartinib Dihydrochloride) by Daiichi Sankyo: FDA Orange Book core substance LOE 2028-09-26 (last listed 2033-09-30), 0 AB generics, $10.7M 2024 CMS Part D & Medicaid spend, and $15,288 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorDaiichi Sankyo
FDA Application & PathwayN216993 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2028-09-26
Last Listed Patent or Exclusivity Date2033-09-30
Orange Book Patents (*PED Extensions)11 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$10.7M
2024 Medicare Part D Spend$7.9M
2024 Medicaid Spend$2.9M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($15,288 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Daiichi Sankyo across sibling Meru public-data platforms.